Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center feasibility trial of patients with borderline resectable
pancreatic adenocarcinoma receiving radiation therapy with Stereotactic body radiation
therapy (SBRT) and chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by
pancreatectomy.